

Marck Biosciences to enter Singapore, Malaysia market

First Indian pharmaceutical company to get NPCB approval for small volume parenterals

DNA Money Correspondent. Ahmedabad

Marck Biosciences, a leading manufacturer and marketer of sterile dosages pharma products and blow-fill-seal specialist, today announced its plan to enter Singapore and Malaysian market.

The company said that its manufacturing facility had received an approval from the NPCB (National Pharmaceutical Control Bureau), ministry of health, Malaysia for large volume parenterals, small volume parenterals & ophthalmics. Marck is the only company in India to have received the NPCB approval for its small volume parenterals facility. Marck, which has presence in around 70 countries across the world, plans to introduce a range of small volume parenterals including ophthalmics, irrigation solutions, injectibles and respiratory solutions, and IV parenterals formulations in the large volume parenterals in Singapore and Malaysia.

Commenting on the development, Bhavesh Patel, managing director of the company, said,



"The NPCB approval has significant implications for Marck. Our early entry into Malaysia and Singapore opens up a large export market for our products. The manufacturers of these countries can now get their brands outsourced from Marck. Since NPCB is a participant of PIC/S - The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme - which has 36 participating authorities including those from the UK and Australia, the approval will help our registrations endeavor in other PIC/S member countries."

"With the NPCB approval and the most modern SVP & LVP capacity, we will efficiently cater to Malaysia, Singapore and Brunei with our vast product range," Patel added.